Inactive Instrument

diaDexus, Inc. Share Price OTC Bulletin Board

Pharmaceuticals

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

17/09/21	Diadexus, Inc. Went Out of Business	CI
08/06/18	Motion for Asset Sale Approved for Diadexus, Inc.	CI

on all subscriptions*

Last hours

Enjoy this offer

* See conditions under "Our services"

Diadexus, Inc. is a diagnostics company. The Company is engaged in developing and commercializing products that deliver healthcare providers with relevant information to assist in the management of patients throughout the course of cardiac disease. Its capabilities include manufacturing, assay development, Food and Drug Administration (FDA) regulatory clearance, and marketing and selling products. Its commercially-available products consist of two FDA-cleared tests to measure Lp-PLA2: the PLAC Test ELISA Kit (the PLAC ELISA Test) and the PLAC Test for Lp-PLA2 Activity (the PLAC Activity Test). Its other products include proADM; proET-1, which aids in predication of heart failure, and proANP, which aids in predication of heart failure. The Company sells its diagnostic products to laboratories and promotes these products to the laboratories' sales representatives, as well as directly to healthcare providers.

Employees

Sector

Pharmaceuticals

More about the company

Market Cap	49.2K 42.9K 39.73K 37.19K 69.75K 4.64M 70.17K 471K 183K 2.29M 185K 181K 7.93M	P/E 2014	-3.26x	P/E 2015	-1.14x
Enterprise Value	5.29M 4.61M 4.27M 4M 7.5M 499M 7.55M 50.68M 19.64M 246M 19.86M 19.43M 853M	EV / Sales 2014	1.05x	EV / Sales 2015	0.77x
Free-Float	100%	Yield 2014 *	-	Yield 2015	-

17/09/21	Diadexus, Inc. Went Out of Business	CI
08/06/18	Motion for Asset Sale Approved for Diadexus, Inc.	CI
09/05/18	Motion for Asset Sale Filed by Diadexus, Inc.	CI
31/07/16	Diazyme Laboratories, Inc. completed the acquisition of operational assets from Diadexus, Inc. (OTCPK:DDXS.Q).	CI
29/07/16	Motion for Asset Sale Approved for Diadexus, Inc.	CI
28/07/16	General Atomics Corp. entered into purchase agreement to acquire operational assets from Diadexus, Inc. (OTCPK:DDXS.Q) for $4.8 million.	CI
19/07/16	Cleveland HeartLab, Inc. cancelled the acquisition of operational assets from Diadexus, Inc. (OTCPK:DDXS.Q).	CI
07/07/16	Motion for Asset Sale Filed by Diadexus, Inc.	CI
06/07/16	Cleveland HeartLab, Inc. agreed to acquire operational assets from Diadexus, Inc. (OTCPK:DDXS.Q) for $7 million.	CI
13/06/16	Diadexus, Inc. Filed for Bankruptcy	CI
10/06/16	Diadexus, Inc. Announces Resignation of Leone Patterson as Chief Financial Office	CI
23/05/16	Diadexus, Sonic Healthcare USA Sign National Agreement for PLAC Activity Test	CI
29/04/16	Diadexus, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2016	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ULTRAGENYX PHARMACEUTICAL INC.	+1.97%	+12.69%	-26.53%	-43.16%	2.69B
SAREPTA THERAPEUTICS, INC.	+3.36%	+14.50%	-15.60%	-86.56%	1.85B
BIONOTE, INC.	+0.22%	-4.72%	-9.90%	-3.93%	307M
DK LIFE SCIENCE CO., LTD.	-4.70%	-5.69%	-40.54%	-	57.14M
Average	+0.21%	+4.57%	-23.14%	-44.55%	1.23B
Weighted average by Cap.	+2.31%	+13.81%	-21.53%	-57.24%

	2014	2015
Net sales	26.11M 22.77M 21.09M 19.74M 37.02M 2.46B 37.24M 250M 96.95M 1.21B 98.02M 95.91M 4.21B	17.88M 15.59M 14.44M 13.52M 25.35M 1.69B 25.51M 171M 66.4M 831M 67.13M 65.69M 2.88B
Net income	-8.47M -7.38M -6.84M -6.4M -12M -799M -12.08M -81.11M -31.44M -393M -31.78M -31.1M -1.37B	-7.17M -6.25M -5.79M -5.42M -10.16M -676M -10.22M -68.65M -26.61M -333M -26.9M -26.32M -1.16B
Net Debt	-198K -173K -160K -150K -281K -18.68M -282K -1.9M -735K -9.2M -743K -727K -31.93M	5.24M 4.57M 4.23M 3.96M 7.43M 495M 7.48M 50.21M 19.46M 243M 19.67M 19.25M 845M

diaDexus, Inc. Share Price OTC Bulletin Board

Stocks

Pharmaceuticals

Valuation: diaDexus, Inc.

Latest news : diaDexus, Inc.

Diagnostic & Testing Substances Manufacturers

Financials

Company Profile